Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)
China flag China · Delayed Price · Currency is CNY
26.72
+0.04 (0.15%)
Apr 28, 2026, 3:00 PM CST

SHA:600566 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
5,9016,2197,9979,6388,9767,618
Other Revenue
--20.3816.5119.8713
5,9016,2198,0179,6558,9967,631
Revenue Growth (YoY)
-17.35%-22.43%-16.96%7.32%17.90%23.77%
Cost of Revenue
1,1781,3091,6661,7841,5371,277
Gross Profit
4,7234,9106,3507,8717,4596,354
Selling, General & Admin
2,4312,5593,3874,3794,4774,031
Research & Development
390.98385.1444.78464.4553.3523.44
Other Operating Expenses
78.888.75115.38146.24138.81120.9
Operating Expenses
2,9003,0333,9254,9875,2054,683
Operating Income
1,8231,8772,4262,8842,2541,671
Interest Expense
---27.27-17.58-30.41-34.9
Interest & Investment Income
186.93189.89352.77357.81183.21171.42
Other Non Operating Income (Expenses)
63.6354.13-1.03-0.83-1.2-0.41
EBT Excluding Unusual Items
2,0732,1212,7503,2232,4051,807
Gain (Loss) on Sale of Investments
48.6441.3199.214.6-7.32114.55
Gain (Loss) on Sale of Assets
0.170.170.20.135.220.65
Asset Writedown
-0.48-0.47-0.28-1.09-0.53-0.42
Other Unusual Items
--128.9860.42105.0928.96
Pretax Income
2,1222,1622,9783,2972,5081,950
Income Tax Expense
385.72383.99441.54470.03336.2233.22
Earnings From Continuing Operations
1,7361,7782,5372,8272,1721,717
Minority Interest in Earnings
1.62-0.41-5.15-4.28-0.971.96
Net Income
1,7381,7782,5322,8232,1711,719
Net Income to Common
1,7381,7782,5322,8232,1711,719
Net Income Growth
-18.29%-29.77%-10.32%30.04%26.27%34.60%
Shares Outstanding (Basic)
919921917916890886
Shares Outstanding (Diluted)
919921917916908900
Shares Change (YoY)
0.25%0.43%0.08%0.91%0.91%7.82%
EPS (Basic)
1.891.932.763.082.441.94
EPS (Diluted)
1.891.932.763.082.391.91
EPS Growth
-18.50%-30.07%-10.39%28.87%25.13%24.84%
Free Cash Flow
1,0211,1022,0023,1622,3771,646
Free Cash Flow Per Share
1.111.202.183.452.621.83
Dividend Per Share
--2.0901.3000.8800.680
Dividend Growth
--60.77%47.73%29.41%51.11%
Gross Margin
80.04%78.95%79.21%81.52%82.91%83.27%
Operating Margin
30.89%30.19%30.26%29.87%25.05%21.89%
Profit Margin
29.45%28.59%31.58%29.24%24.13%22.53%
Free Cash Flow Margin
17.30%17.73%24.97%32.76%26.42%21.57%
EBITDA
2,1342,1872,7273,1852,5611,964
EBITDA Margin
36.17%35.16%34.01%32.99%28.47%25.74%
D&A For EBITDA
311.39309.33301.08301.2307.14293.13
EBIT
1,8231,8772,4262,8842,2541,671
EBIT Margin
30.89%30.19%30.26%29.87%25.05%21.89%
Effective Tax Rate
18.18%17.76%14.83%14.26%13.41%11.96%
Revenue as Reported
--8,0179,6558,9967,631
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.